58.22 +0.33 (0.57%)
After hours: 7:30PM EDT
|Bid||58.22 x 1100|
|Ask||58.35 x 1800|
|Day's Range||57.28 - 58.10|
|52 Week Range||42.48 - 68.34|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||112.85|
|Forward Dividend & Yield||1.80 (3.12%)|
|Ex-Dividend Date||Jul. 02, 2020|
|1y Target Est||N/A|
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndrome
FDA Approves Opdivo for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) ....
NEW YORK, June 08, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY.RT)..
New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients....
BMS Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia in Patients w/ Moderate to Severe Ulcerative Colitis
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA®, a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
PHILADELPHIA and BALTIMORE, May 28, 2020 -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer.
BMS Receives European Commission Approval for Zeposia for Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
FDA Approves Opdivo + Yervoy Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases
FDA Approves Opdivo + Yervoy as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1≥1%
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi sarcoma
NEW YORK, NY / ACCESSWIRE / May 14, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bristol-Myers Squibb Company ("Bristol-Myers" or "the ...
Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy....
Opdivo + Yervoy with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line....
BMS & bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients
BMS and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
GRYT Health and Bristol Myers Squibb Team Up to Launch COVID Advocacy Exchange for Patient Advocates